Fate Therapeutics (FATE) PT Lowered to $6 at BMO Capital
Tweet Send to a Friend
BMO Capital analyst Etzer Darout lowered the price target on Fate Therapeutics (NASDAQ: FATE) to $6.00 (from $7.00) while maintaining ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
